Stockscreener 앱 받기
0.692
2.91%
0.0196
시장 영업 전:
.71
0.018
+2.60%
전일 마감가:
$0.6724
열려 있는:
$0.677
하루 거래량:
224.88K
Relative Volume:
1.43
시가총액:
$47.74M
수익:
$9.53M
순이익/손실:
$-44.61M
주가수익비율:
-0.7604
EPS:
-0.91
순현금흐름:
$-38.32M
1주 성능:
-11.96%
1개월 성능:
+6.00%
6개월 성능:
-36.51%
1년 성능:
-35.93%
1일 변동 폭
$0.65
$0.71
1주일 범위
$0.65
$0.793
52주 변동 폭
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
명칭
Cue Biopharma Inc
전화
617-949-2680
주소
40 GUEST STREET, BOSTON, MA
CUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.692 | 47.74M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-13 | 개시 | Jefferies | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2022-11-21 | 개시 | Piper Sandler | Overweight |
| 2022-01-13 | 개시 | H.C. Wainwright | Buy |
| 2022-01-03 | 개시 | Craig Hallum | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-04-09 | 개시 | Stifel | Buy |
| 2020-01-28 | 개시 | BTIG Research | Buy |
| 2020-01-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Cue Biopharma Inc 주식(CUE)의 최신 뉴스
Millennium Management LLC Reduces Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Bank of America Corp DE Acquires 85,113 Shares of Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
CueBiopharma (CUE) Appoints Interim CFO as Kerri-Ann Millar Resi - GuruFocus
Cue Biopharma CFO Kerri-Ann Millar to Depart - marketscreener.com
Cue Biopharma CFO Resignation and Board Appointment - TipRanks
Cue Biopharma CEO Daniel Passeri To Serve As Interim CFO - marketscreener.com
Jane Street Group LLC Has $70,000 Stock Holdings in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by Northern Trust Corp - Defense World
Stifel Financial Corp Grows Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Transcript : Cue Biopharma, Inc.Special Call - marketscreener.com
Cue Biopharma Inc Reports Q1 2025 Earnings: EPS of -$0.17 Misses Estimate, Revenue Falls Short at $0.4 Million - GuruFocus
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates - MSN
Cue Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cue Biopharma (CUE) Reports Revenue Miss for Q1 2025 | CUE Stock News - GuruFocus
Cue Biopharma Reports Strategic Collaboration with Boehringer Ingelheim and Financial Results for Q1 2025 - Nasdaq
Cue Biopharma (CUE) Schedules Virtual Investor Event to Showcase Biologics Platform | CUE Stock News - GuruFocus
Cue Biopharma to Host Virtual Investor Event on May 15, 2025 - The Manila Times
Cue Biopharma to Participate in Fireside Chat at the Citizens Li - GuruFocus
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference - The Manila Times
Cue Biopharma Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Grows Stake in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
LPL Financial LLC Has $47,000 Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
CUECue Biopharma Inc Latest Stock News & Market Updates - Stock Titan
Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia
Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa
Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals
Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN
Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus
Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology
Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq
Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma
Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech
Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard
Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter
Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India
Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia
Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus
Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus
Cue Biopharma Inc (CUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):